A company called Introgen Therapeutics has asked the FDA to grant priority review for a gene-based medication called Advexin p53, a treatment for recurrent head and neck cancers. This is the first application in the USA for approval to market a gene-based medicine.
Filed under: Drugs in development, Management, Treatment, Uncategorized | 1 Comment »
Skip Lockwood of the National Prostate Cancer Coalition is urgently looking for patients willing to discuss their personal stories with the American media. The gist of the story is the need for new diagnostics and the reporter is looking for patients who feel that they would have had better outcomes with better diagnostics like imaging [...]
Filed under: Uncategorized | Comments Off
… and some of them are particularly relevant to prostate cancer. See, for example:
Your lifestyle, your genes, and your cancer
A deadly disparity and
The doctor factor
These stories and other cancer-related stories are all available on line.
Filed under: Uncategorized | No Comments »
We had assembled in the early morning of Father’s Day. We were at the studio of Maestro, well into his Sunday morning gospel show on 99 JAMZ. The reason: to do the most fatherly of interviews, an interview about prostate exams.
Diva Shirley Mordock sat to my left. On Maestro’s cue, she let loose sounds [...]
Filed under: Uncategorized | No Comments »
For the first time, the American Urological Association (AUA) has made all the abstracts and many of the posters presented at their annual meeting (held in Orlando last month) available free and on line. This means that you can go look at the details of many of the presentations yourself if you are interested.
You do [...]
Filed under: Uncategorized | No Comments »
According to data published yesterday in the Journal of the National Cancer Institute, after adjustment for inflation, the average cost for treatment of a newly-diagnosed patient with prostate cancer actually fell by $196 (1.0 percent) between 1991 and 2002, to an average of $18,261 (because fewer men got surgery). By comparison the costs of treating newly diagnosed [...]
Filed under: Uncategorized | 2 Comments »
According to a report in the June 1 issue of Cancer, researchers have uncovered new information about why metastatic prostate cancer may progress following failure of androgen-deprivation therapy (ADT).
Filed under: Uncategorized | No Comments »
In reviewing the many prostate cancer presentations given at the AUA during last week, we have noted several that are certainly worth bringing to the attention of our readers and that have not previously been reported.
Filed under: Uncategorized | 7 Comments »
The following major new content pages have been added to the main web site over the past week:
High intensity focused ultrasound in treatment of early stage (localized) prostate cancer
Orchiectomy in treatment of metastatic prostate cancer
Luteinizing hormone releasing hormone (LHRH) agonists in treatment of metastatic prostate cancer
Luteinizing hormone releasing hormone (LHRH) antagonists in treatment of metastatic prostate cancer
Nonsteroidal [...]
Filed under: Uncategorized | No Comments »
The “New” Prostate Cancer InfoLink is pleased to announce that Judd W. Moul, MD, FACS, professor and chief, Division of Urologic Surgery, and director of the Duke Prostate Center, Duke University Health System, Durham, NC, has agreed to become the chairman of a scientific advisory board to our web services. In forthcoming weeks we [...]
Filed under: Uncategorized | No Comments »
